# A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

> **NCT02608697** · PHASE2 · COMPLETED · sponsor: **Catabasis Pharmaceuticals** · enrollment: 153 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** CAT-2054
- **DRUG:** Placebo
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT02608697
- **Lead sponsor:** Catabasis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-05
- **Final completion:** 2016-06
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02608697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02608697, "A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02608697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*